Navigation Links
MIT: The tallest tree in the land
Date:7/18/2011

is back down to the roots. This pumping capacity, or fluid flow rate, is a bit of a balancing act: Trees of a given size have certain rates of metabolism that pump enough water and nutrients to survive without using up all of the available resources, such as light and water.

The team drew up an "idealized tree" to represent an average model of all tree species in the United States and developed equations to represent the relationships between fluid flow rate, tree size, and meteorological factors such as average temperature, rainfall, humidity and sunlight.

Putting their model to work, the group predicted the height of the tallest trees across the country, using local meteorological data. Kempes compared the team's results with actual measurements from the United States Forest Service. The predictions from the model matched up well with the Forest Service data, except for two geographic regions: the arid Southwest and parts of New England.

In the Southwest, the team found that trees actually grew taller than the model predicted, possibly due to evolutionary adaptation. "Deserts are where you find many specialized trait adaptations," Kempes says. "This is where you have weird traits that can deal with harsh environments."

In New England, trees were a bit shorter than predicted, primarily because the model did not factor in the area's timber and logging history. New-growth forests simply haven't had time to recover, but if left undisturbed, Kempes says they will eventually catch up with the model's predictions.

The group used the same model to predict what would happen to tree height in the event of global temperature changes, and found that with an increase of 2 degrees Celsius across the country, the average height of the tallest trees would shrink by 11 percent. Conversely, a dip of 2 degrees Celsius would spur trees to sprout up by 13 percent.

Going forward, Kempes and his colleagues plan to use the model to "
'/>"/>

Contact: Caroline McCall
cmccall5@mit.edu
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... JUPITER, FL, October 26, 2010 The Scripps Research Institute ... Fox Foundation to study a pair of genetic mutations that ... for Parkinson,s disease, a progressive and fatal neurodegenerative disorder. ... director for drug discovery at Scripps Florida, is the principal ...
... the brain, which scavenge pathogens and damaged neurons, are also ... by Duke neuroscientists. Earlier studies by Staci Bilbo, an ... rats experiencing an infection at an early age have an ... learning and memory. In a study published in ...
... has a companion among emerging futuristic "e-sensing" devices intended ... is a "magnetic tongue" -- a method used to ... sweet, bitter, sour, etc. A report on use of ... Journal of Agricultural and Food Chemistry . ...
Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... CARLOS, Calif., Jan. 5 Nektar Therapeutics,(Nasdaq: ... Robin, is,scheduled to present at the upcoming 27th Annual ... St. Francis Hotel on Tuesday,January 13, 2009 at 10:00 ... The presentation will be accessible via ...
... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7